Lehnerer, Sophie http://orcid.org/0000-0001-9007-027X
Jacobi, Jonas
Schilling, Ralph
Grittner, Ulrike
Marbin, Derin
Gerischer, Lea
Stascheit, Frauke
Krause, Maike
Hoffmann, Sarah
Meisel, Andreas
Clinical trials referenced in this document:
Documents that mention this clinical trial
Burden of disease in myasthenia gravis: taking the patient’s perspective
https://doi.org/10.1007/s00415-021-10891-1
Article History
Received: 29 June 2021
Revised: 10 October 2021
Accepted: 2 November 2021
First Online: 20 November 2021
Change Date: 12 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-022-11290-w
Declarations
:
: Financial: Sophie Lehnerer and Sarah Hoffmann have received speaker’s honoraria and honoraria for attendance at advisory boards from Alexion. Maike Krause received speaker’s honoraria from Argnx. Frauke Stascheit received speaker’s honoraria from Alexion. Andreas Meisel received speaker’s honoraria from Alexion, Grifols and Hormosan. He received honoraria from Alexion, UCB, MorphoSys and Argnx for consulting services and financial research support from Octapharma and Alexion. All other authors report no disclosures relevant to the manuscript. Non-financial: Andreas Meisel is Chairman of the medical advisory board of the German Myasthenia Gravis Society.
: The study was conducted in accordance to the declaration of Helsinki and received ethics approval by the institutional ethics committee of Charité University Medicine Berlin (EA1/008/19). The study was conducted in accordance to the declaration of Helsinki and the STROBE reporting guidelines and was registered on clinicaltrials.gov (NCT03205306).
: Data were obtained by a large questionnaire-based survey. No written informed consent was obtained from the study participants because the data collection was completely anonymous.
: All authors have approved the manuscript for submission, accordingly the manuscript conforms to the journal’s policies. The authors take full responsibility for the data, the analyses and interpretation, and the conduct of the research. They have full access to all of the data, and the right to publish any and all data separate and apart from the guidance of any sponsor.